STOCK TITAN

[Form 4] Outlook Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Outlook Therapeutics director Julian S. Gangolli was granted a non‑employee director stock option on 10/01/2025 to buy 286,734 shares of common stock at an exercise price of $1.04 per share. The option is an annual grant under the company’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan. The option shall fully vest on 10/01/2026 provided the director continues service through that date, and the underlying shares are subject to acceleration on a Change in Control if the director is in service immediately before such event. The filing was reported on Form 4 and signed by an attorney‑in‑fact on behalf of the reporting person.

Il direttore di Outlook Therapeutics, Julian S. Gangolli, ha ricevuto una stock option per direttori non dipendenti il 01/10/2025 per acquistare 286.734 azioni ordinarie a un prezzo di esercizio di $1,04 per azione. L opzione è una concessione annua ai sensi della politica di compensazione per i direttori non dipendenti e del 2024 Equity Incentive Plan. L opzione si maturerà integralmente il 01/10/2026 a condizione che il direttore continui il servizio fino a tale data, e le azioni sottostanti sono soggette ad accelerazione in caso di Cambio di Controllo se il direttore è in servizio immediatamente prima di tale evento. La comunicazione è stata riportata sul modulo Form 4 e firmata da un procuratore ad acta per conto della persona che presenta la relazione.

El director de Outlook Therapeutics, Julian S. Gangolli, recibió una opción de acciones para directores no ejecutivos el 01/10/2025 para comprar 286.734 acciones comunes a un precio de ejercicio de $1,04 por acción. La opción es una concesión anual bajo la Política de Compensación para Directores no Empleados y el Plan de Incentivos de Acciones 2024. La opción deberá quedar totalmente vestida el 01/10/2026 siempre que el director continúe prestando servicios hasta esa fecha, y las acciones subyacentes están sujetas a aceleración en caso de Cambio de Control si el director se encuentra en servicio inmediatamente antes de tal evento. El informe se presentó en el Formulario 4 y fue firmado por un apoderado en nombre de la persona obligada a presentar el informe.

Outlook Therapeutics의 이사인 Julian S. Gangolli가 비직원 이사 주식매수 선택권을 2025-10-01에 부여받아 보통주 286,734주를 주당 행사가 $1.04에 구입할 수 있습니다. 이 옵션은 회사의 비직원 이사 보상 정책 및 2024 Equity Incentive Plan에 따른 연례 부여입니다. 이 옵션은 이사가 그 날짜까지 재직하는 경우 2026-10-01에 완전히 시가권이 부여되며, 기초 주식은 이사 교체 시점의 Change in Control에 따라 가속될 수 있습니다. 이 서류는 Form 4에 보고되었으며 보고자를 대신해 대리인이 서명했습니다.

Le directeur d'Outlook Therapeutics, Julian S. Gangolli, a reçu une option d'achat d'action pour administrateurs non salariés le 01/10/2025 afin d'acheter 286 734 actions ordinaires à un prix d'exercice de 1,04 $ par action. Cette option est une attribution annuelle dans le cadre de la Politique de rémunération des administrateurs non salariés et du Plan d'Incitation à l'Équité 2024. L'option svestira intégralement le 01/10/2026 à condition que le directeur continue à servir jusqu'à cette date, et les actions sous-jacentes sont sujettes à accélération en cas de Changement de contrôle si le directeur est en fonction immédiatement avant l’événement. Le dépôt a été déclaré sur le formulaire Form 4 et signé par un mandataire agissant au nom de la personne déclarant.

Der Direktor von Outlook Therapeutics, Julian S. Gangolli, erhielt eine Aktienoption für nicht ausgeschüttete Direktorinnen und Direktoren am 01.10.2025, um 286.734 Stammaktien zu einem Ausübungspreis von $1,04 pro Aktie zu erwerben. Die Option ist eine jährliche Zuweisung gemäß der Richtlinie zur Vergütung nicht angestellter Direktoren und dem 2024 Equity Incentive Plan. Die Option wird am 01.10.2026 vollständig vesten vorausgesetzt, der Direktor bleibt bis zu diesem Datum im Dienst, und die zugrunde liegenden Aktien unterliegen einer Beschleunigung bei einem Change in Control, wenn der Direktor unmittelbar vor dem Ereignis im Dienst ist. Die Einreichung wurde auf Formular 4 berichtet und von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.

تم منح مدير شركة Outlook Therapeutics، جوليان س. جانولي، خياراً لسهم الشركة للمديرين غير الموظفين في 01/10/2025 لشراء 286,734 سهم من الأسهم العادية بسعر تمارين قدره $1.04 للسهم الواحد. الخيار منحة سنوية بموجب سياسة تعويض المديرين غير الموظفين وخطة الحوافز للأسهم Plan 2024 Equity Incentive. سيكتمل منحه بالكامل في 01/10/2026 بشرط أن يواصل المدير الخدمة حتى ذلك التاريخ، وتخضع الأسهم الأساسية لتسريع عند حدوث تغيير في السيطرة إذا كان المدير في الخدمة Immediately قبل الحدث. تم الإبلاغ عن الإيداع في النموذج Form 4 وتوقيعه من قبل محامٍ بالوكالة نيابة عن الشخص الذي قدم الإبلاغ.

Outlook Therapeutics 的董事 Julian S. Gangolli 获得一项面向非雇员董事的股票期权,授予日为2025-10-01,可以每股$1.04的执行价格购买286,734股普通股。该期权是基于公司非雇员董事薪酬政策及2024 Equity Incentive Plan的年度授予。若董事持续在任至该日期,该期权将于2026-10-01完全归属;且若发生控股变更,且董事在事件发生前仍在任,其所持股票底层权利将会加速归属。该披露已在 Form 4 表格中申报,由代理律师代表披露人签署。

Positive
  • 286,734‑share option grant aligns director incentives with shareholder outcomes
  • Grant is issued under the company’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan, indicating established governance process
  • Vesting schedule (10/01/2026) creates a clear service‑based retention mechanism
Negative
  • None.

Insights

Director received annual option grant of 286,734 shares at $1.04, vesting in one year.

This is a routine non‑employee director compensation action under the issuer’s stated policy and the 2024 Equity Incentive Plan. The award vests on 10/01/2026 contingent on continued service, aligning director incentives with shareholder value over the next year.

The grant includes an acceleration provision upon a Change in Control, which is a common clause that can accelerate equity vesting if the company is acquired and the director remains in service immediately before the transaction.

Il direttore di Outlook Therapeutics, Julian S. Gangolli, ha ricevuto una stock option per direttori non dipendenti il 01/10/2025 per acquistare 286.734 azioni ordinarie a un prezzo di esercizio di $1,04 per azione. L opzione è una concessione annua ai sensi della politica di compensazione per i direttori non dipendenti e del 2024 Equity Incentive Plan. L opzione si maturerà integralmente il 01/10/2026 a condizione che il direttore continui il servizio fino a tale data, e le azioni sottostanti sono soggette ad accelerazione in caso di Cambio di Controllo se il direttore è in servizio immediatamente prima di tale evento. La comunicazione è stata riportata sul modulo Form 4 e firmata da un procuratore ad acta per conto della persona che presenta la relazione.

El director de Outlook Therapeutics, Julian S. Gangolli, recibió una opción de acciones para directores no ejecutivos el 01/10/2025 para comprar 286.734 acciones comunes a un precio de ejercicio de $1,04 por acción. La opción es una concesión anual bajo la Política de Compensación para Directores no Empleados y el Plan de Incentivos de Acciones 2024. La opción deberá quedar totalmente vestida el 01/10/2026 siempre que el director continúe prestando servicios hasta esa fecha, y las acciones subyacentes están sujetas a aceleración en caso de Cambio de Control si el director se encuentra en servicio inmediatamente antes de tal evento. El informe se presentó en el Formulario 4 y fue firmado por un apoderado en nombre de la persona obligada a presentar el informe.

Outlook Therapeutics의 이사인 Julian S. Gangolli가 비직원 이사 주식매수 선택권을 2025-10-01에 부여받아 보통주 286,734주를 주당 행사가 $1.04에 구입할 수 있습니다. 이 옵션은 회사의 비직원 이사 보상 정책 및 2024 Equity Incentive Plan에 따른 연례 부여입니다. 이 옵션은 이사가 그 날짜까지 재직하는 경우 2026-10-01에 완전히 시가권이 부여되며, 기초 주식은 이사 교체 시점의 Change in Control에 따라 가속될 수 있습니다. 이 서류는 Form 4에 보고되었으며 보고자를 대신해 대리인이 서명했습니다.

Le directeur d'Outlook Therapeutics, Julian S. Gangolli, a reçu une option d'achat d'action pour administrateurs non salariés le 01/10/2025 afin d'acheter 286 734 actions ordinaires à un prix d'exercice de 1,04 $ par action. Cette option est une attribution annuelle dans le cadre de la Politique de rémunération des administrateurs non salariés et du Plan d'Incitation à l'Équité 2024. L'option svestira intégralement le 01/10/2026 à condition que le directeur continue à servir jusqu'à cette date, et les actions sous-jacentes sont sujettes à accélération en cas de Changement de contrôle si le directeur est en fonction immédiatement avant l’événement. Le dépôt a été déclaré sur le formulaire Form 4 et signé par un mandataire agissant au nom de la personne déclarant.

Der Direktor von Outlook Therapeutics, Julian S. Gangolli, erhielt eine Aktienoption für nicht ausgeschüttete Direktorinnen und Direktoren am 01.10.2025, um 286.734 Stammaktien zu einem Ausübungspreis von $1,04 pro Aktie zu erwerben. Die Option ist eine jährliche Zuweisung gemäß der Richtlinie zur Vergütung nicht angestellter Direktoren und dem 2024 Equity Incentive Plan. Die Option wird am 01.10.2026 vollständig vesten vorausgesetzt, der Direktor bleibt bis zu diesem Datum im Dienst, und die zugrunde liegenden Aktien unterliegen einer Beschleunigung bei einem Change in Control, wenn der Direktor unmittelbar vor dem Ereignis im Dienst ist. Die Einreichung wurde auf Formular 4 berichtet und von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gangolli Julian S

(Last) (First) (Middle)
C/O OUTLOOK THERAPEUTICS, INC.
111 S. WOOD AVE, UNIT #100

(Street)
ISELIN NJ 08830

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.04 10/01/2025 A 286,734 (1) 10/01/2035 Common Stock 286,734 $0 286,734 D
Explanation of Responses:
1. This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control.
/s/Lawrence A. Kenyon, Attorney-in-Fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What option was reported for Outlook Therapeutics (OTLK)?

A stock option to purchase 286,734 shares of common stock at an exercise price of $1.04 was reported.

When was the transaction date and who is the reporting person for OTLK?

The transaction date is 10/01/2025 and the reporting person is director Julian S. Gangolli.

When does the option vest and are there acceleration terms?

The option fully vests on 10/01/2026 subject to continuous service and includes acceleration upon a Change in Control if service is continuous immediately prior.

Under what plans or policies was the grant made?

The grant was made under the issuer’s Non‑Employee Director Compensation Policy and the 2024 Equity Incentive Plan.

How was the Form 4 signed and filed?

The Form 4 was signed on behalf of the reporting person by an attorney‑in‑fact (Lawrence A. Kenyon) on 10/03/2025.
Outlook Therapeutics Inc

NASDAQ:OTLK

OTLK Rankings

OTLK Latest News

OTLK Latest SEC Filings

OTLK Stock Data

47.53M
28.25M
36.39%
20.54%
15.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
ISELIN